Differential Impact of Postoperative Radiotherapy on Survival Across Clinical Treatment Score Post-5 Years Risk Categories in Early-Stage Luminal Breast Cancer After Breast-Conserving Surgery
Clinical Breast Cancer · 2026-12 · 26 (12) · 13-20
DOI: 10.1016/j.clbc.2026.10.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-12. Verfasst von Guan-Qiao Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital), Haikou, Hainan, PR China. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Fujian Provincial Natural Science Foundation.
Abstract (Originalsprache)
PURPOSE: To evaluate the role of Clinical Treatment Score post-5 years (CTS5) in stratifying post-operative radiotherapy (PORT) benefits in patients with T1-2N0, estrogen receptor-positive breast cancer (BC) after breast-conserving surgery (BCS). METHODS: We included patients whose survival duration ≥ 60 months using the data from the Surveillance, Epidemiology, and End Results database. The association between CTS5 and survival was assessed. RESULTS: A total of 23504 patients were included. The majority of patients (n = 19334, 82.3%) were classified as low CTS5, 3792 (16.1%) as intermediate CTS5, and 378 (1.6%) as high CTS5. The low CTS5 group exhibited significantly superior BCSS (P < .001) and OS (P < .001) than the intermediate and high CTS5 groups. While CTS5 was confirmed as an independent prognostic factor for breast cancer-specific survival (BCSS) and overall survival (OS), its interaction with PORT efficacy was paradoxical. Contrary to the hypothesis that higher-risk patients would derive the greatest benefit, the survival advantage of PORT was predominantly observed in the low CTS5 group, where PORT significantly improved both BCSS (P = .004) and OS (P < .001). Conversely, in patients with intermediate and high CTS5 scores, PORT did not confer a significant benefit regarding BCSS or OS. CONCLUSIONS: CTS5 serves as a robust independent prognostic indicator and a cost-effective tool for risk stratification. The benefit of PORT in early-stage BC is most pronounced in low CTS5 patients. These findings highlight the potential of CTS5 as a stratification tool for identifying differential PORT benefit, although its role in prospectively guiding PORT selection requires validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, Hainan Affiliated Hospital of Hainan Medical University (Hainan General Hospital), Haikou, Hainan, PR China.
- Guangdong Experimental High School, Guangzhou, PR China.
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, PR China. Electronic address: zhoujuan@xmu.edu.cn.
- Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, PR China. Electroni…
Förderung
- Fujian Provincial Natural Science Foundation
Zitieren
APA
Li, G. Q., Kemu, Q. L. Y., He, X. Z., Zhou, J., & Wu, S. G. (2026). Differential Impact of Postoperative Radiotherapy on Survival Across Clinical Treatment Score Post-5 Years Risk Categories in Early-Stage Luminal Breast Cancer After Breast-Conserving Surgery. Clinical Breast Cancer, 26(12), 13-20. https://doi.org/10.1016/j.clbc.2026.10.007
Vancouver
Li GQ, Kemu QLY, He XZ, Zhou J, Wu SG. Differential Impact of Postoperative Radiotherapy on Survival Across Clinical Treatment Score Post-5 Years Risk Categories in Early-Stage Luminal Breast Cancer After Breast-Conserving Surgery. Clinical Breast Cancer. 2026;26(12):13-20. doi:10.1016/j.clbc.2026.10.007
BibTeX
@article{Li2026,
author = {Li, Guan-Qiao and Kemu, Qiao Li-Pan Ye and He, Xi-Zong and Zhou, Juan and Wu, San-Gang},
title = {Differential Impact of Postoperative Radiotherapy on Survival Across Clinical Treatment Score Post-5 Years Risk Categories in Early-Stage Luminal Breast Cancer After Breast-Conserving Surgery},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {12},
pages = {13--20},
doi = {10.1016/j.clbc.2026.10.007}
}
EUVIMED